Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous mesenchymal stem cells (Ministry of Public Health, Republic of Belarus)
- Development stage
- Unknown
- Lead developer
- Ministry of Health of Belarus
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intrathecal
01
Overview
This experimental cell therapy, developed by the Ministry of Public Health of the Republic of Belarus, utilizes autologous bone marrow-derived mesenchymal stem cells (MSCs) for the treatment of drug-resistant symptomatic epilepsy. The therapeutic protocol involves a sequential administration: an initial intravenous infusion of ex vivo expanded, undifferentiated MSCs, followed approximately one week later by an intrathecal (endolumbal) injection of a portion of those cells that have undergone neural induction (neuroinduced MSCs). This dual approach aims to leverage the immunomodulatory and neuroprotective properties of MSCs to reduce seizure frequency and severity in patients who do not respond to standard anti-epileptic drugs. Clinical evaluation in a Phase I/II study (NCT02497443) demonstrated a favorable safety profile and potential anticonvulsant efficacy, with some patients achieving seizure remission.
- Other names
- autologous bone marrow-derived mesenchymal stem cellsneuroinduced MSCsneurally-induced autologous MSCs
Beyond the preview
Go deeper on autologous mesenchymal stem cells (Ministry of Public Health, Republic of Belarus).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous mesenchymal stem cells (Ministry of Public Health, Republic of Belarus).